Dendreon shares skyrocket on data deal

Shares of Dendreon shot up 42 percent this morning after the company announced that the FDA would accept interim data analysis from an ongoing clinical trial to supplement its stalled application for Provenge. Dendreon's shares have been on a wild roller coaster ride in recent months, hitting a low point earlier this month when the FDA said it would need more data on Provenge before it could be approved. That decision provoked investor panic that the FDA would want a new clinical trial on the drug, adding years of unexpected delays. This morning Dendreon said that regulators would accept "either a positive interim or final analysis of survival" from an ongoing study. Interim data is expected next year.

- read the AP report on Provenge

Related Articles:
Shareholders blast Dendreon. Report
Dendreon slashes jobs as it repositions. Report
Dendreon looks at restructuring after FDA move. Report
Dendreon gets approvable letter for Provenge. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.